text: nferreyros – Community Oncology Alliance
  Author: nferreyros
  About nferreyros
  So far nferreyros has created 11 blog entries.
  All Types Annual & Mid-Year Reports (2) Annual Conferences (4) COA in the News (296) Fact Sheets (0) Featured (4) Hill Days & Fly Ins (0) Horror Stories (5) Issue Briefs & Overviews (14) Latest News (659) Latest News previous year (2,805) Member News (11) Payer Exchange Summits (4) Position Statements & Comment Letters (21) Practice Impact Reports (2) Presentations (3) Press Releases & Statements (93) Publications (55) State of the Union Briefings (2) Studies & Reports (47) Uncategorized (5) Webinars (3)
  All Authors Avalere Health Avalere Health Berkeley Research Group Berkeley Research Group COA Community Oncology Alliance Community Oncology Alliance (COA) Dr. Lucio Gordan Frier Levitt Government & Government Agencies Leavitt Partners Lucio Gordan, Amy Grogg, Marlo Blazer, Barry Fortner Lucio Gordan, Marlo Blazer, Vishal Saundankar, Denise Kazzaz, Susan Weidner, and Michael Eddy Lucio N. Gordan, MD, Marlo Blazer, PharmD, BCOP Milliman Moran Moran Ted Okon Test Author The Hill
  COA Applauds the Senate Finance Committee for PBM Hearing as Part of National Efforts to Shed Light on PBM Abuses and Lower Drug Prices More Investigation and Oversight Needed to Examine Adverse Impact of PBM Abuses on Patient Care Statement from Ted Okon, Executive Director, Community Oncology Alliance (COA): Today's Senate Finance Committee hearing
  2019-04-09T13:38:14-04:00	April 9, 2019|Latest News, Member News, Press Releases & Statements|Comments Off on PBM Middlemen Continue to Dodge Responsibility for Patient Suffering and Rising Drug Prices
  COA in the News, Latest News, Member News, Press Releases & Statements
  Pharmacy Benefit Manager (PBM) Abuses and Patient Horror Stories Take Center Stage at Annual COA Conference Physicians, Administrators, Nurses, Pharmacists, Advocates, and Stakeholders Come Together to Share Latest Innovations in Cancer Care The most successful Community Oncology Alliance (COA) Community Oncology Conference ever, wrapped up today featuring a record-breaking nearly 1,600 community oncology physicians,
  2019-04-16T13:37:07-04:00	April 5, 2019|COA in the News, Latest News, Member News, Press Releases & Statements|Comments Off on COA Hosts Cancer Care Teams, Advocates, and Stakeholders for Largest Community Oncology Conference Ever
  COA Comments: CMS CAR-T Cell Therapy Proposed Coverage Determination
  COA Submits Formal Comments to CMS on Proposed CAR-T Cell Therapy Coverage Determination Today the Community Oncology Alliance (COA) submitted a formal comment letter to the Centers for Medicare & Medicaid Services (CMS) regarding a proposed national coverage determination memo for CAR-T cell therapy. While COA is pleased that CMS is moving in the
  2019-04-09T16:23:23-04:00	March 15, 2019|Press Releases & Statements|Comments Off on COA Comments: CMS CAR-T Cell Therapy Proposed Coverage Determination
  Annual & Mid-Year Reports, Latest News, Member News, Publications
  2019-04-09T16:08:49-04:00	February 6, 2019|Annual & Mid-Year Reports, Latest News, Member News, Publications|Comments Off on Community Oncology Alliance: 2018 Year in Review
  COA Applauds HHS for Taking Strong Step Towards Ending Secretive Rebate System
  COA Commends Trump Administration for Plan to Lower Drug Costs for Patients The Community Oncology Alliance (COA) applauds President Donald Trump, Health and Human Services Secretary Alex Azar, Inspector General Daniel Levinson, and HHS staff for the just released, ambitious proposal to overhaul the nation's secretive drug rebate system. This move will lower drug prices
  2019-02-01T09:15:31-04:00	February 1, 2019|Latest News, Member News, Press Releases & Statements|Comments Off on COA Applauds HHS for Taking Strong Step Towards Ending Secretive Rebate System
  The Myth of Perverse Physician Incentives: Examining Research and Accusations in the Medicare Part B ASP Reimbursement System for Oncology
  A frequent accusation aimed at physicians who prescribe and administer medications within the Medicare Part B system is that they are motivated by a perverse incentive of higher reimbursement to prescribe expensive drugs. For oncologists, who utilize potentially life-saving, but increasingly very expensive drugs in treating some of the nation's sickest patients, this is a
  2018-12-31T14:03:15-04:00	December 31, 2018|Publications|Comments Off on The Myth of Perverse Physician Incentives: Examining Research and Accusations in the Medicare Part B ASP Reimbursement System for Oncology
  Featured, Member News, Position Statements & Comment Letters
  The Honorable Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Attention: CMS-5528-ANPRM P.O. Box 8016 Baltimore, MD 21244-8013 Re: Medicare Program; International Pricing Index Model for Medicare Part B Drugs; CMS-5528- ANPRM Dear Administrator Verma: On behalf of the Board of Directors of the Community Oncology Alliance (COA),
  2019-01-31T16:54:45-04:00	December 31, 2018|Featured, Member News, Position Statements & Comment Letters|Comments Off on COA Comments on IPI for Medicare Part B Drugs
  Position Statements & Comment Letters, Publications
  2018-12-20T11:06:28-04:00	December 16, 2018|Position Statements & Comment Letters, Publications|Comments Off on COA Comments Objecting to CVS-Aetna Merger
  New CPAN Chapter Gives Cancer Patients, Survivors A Forum to Speak Out for Access to Local Cancer Care The Cancer Center of Middle Georgia (CCMG) at the practice's offices at 2400 Bellevue Road, Suite #26, in Dublin, launched a new local chapter of the Community Oncology Alliance Patient Advocacy Network (CPAN), which will advocate for
  2019-01-11T07:02:57-04:00	December 3, 2018|Latest News previous year, Press Releases & Statements|Comments Off on Cancer Center of Middle Georgia Launches Local Chapter of National Advocacy Organization
  COA needs your support for 2019!
  We are about to enter a critical period for community oncology. Far-reaching Medicare policies are under consideration in Washington that have the potential to completely transform your practice and, quite possibly, ability to survive. From the way you and your practice are reimbursed; to how you acquire and deliver complex cancer drugs; to your ability
  2018-11-29T17:45:40-04:00	November 29, 2018|Member News|Comments Off on COA needs your support for 2019!